832.84MMarket Cap-3727P/E (TTM)
12.597High11.450Low461.16KVolume12.490Open12.500Pre Close5.62MTurnover1.05%Turnover RatioLossP/E (Static)68.32MShares12.97052wk High1.95P/B533.48MFloat Cap4.92052wk Low--Dividend TTM43.76MShs Float54.850Historical High--Div YieldTTM9.17%Amplitude4.920Historical Low12.193Avg Price1Lot Size
Replimune Stock Forum
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune presented positive data from its RP1 and RP2 clinical programs at the 2024 ASCO Annual Meeting. The IGNYTE trial showed a 32.7% overall response rate (ORR) for RP1 plus nivolumab in anti-PD-1 failed melanoma, with responses lasting over six months and a median duration exceeding 36 months. RP2, both as monotherapy and in co...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$